Enflicoxib (Daxocox) for Canine Osteoarthritis: A Once-Weekly COX-2 Selective NSAID

Bottom line

• Enflicoxib (Daxocox) is a COX-2 selective coxib-class non-steroidal anti-inflammatory drug (NSAID) centrally authorised in the European Union for the treatment of pain and inflammation associated with osteoarthritis (OA) in dogs [2].
• Its defining practical feature is a once-weekly oral maintenance interval after an initial loading dose — a departure from the daily administration of most canine NSAIDs — which directly targets owner adherence, the recurring weak point in chronic OA management [2].
• As of July 2026, the pivotal evidence is a single 6-month multicentre, blinded, randomised, placebo-controlled field study (n=109): clinical-sum-score (CSS) responder rates were 71.6%, 74.6%, and 71.6% on days 44, 135, and 189, each significantly higher than placebo (41.7%, 33.3%, 20.8%; p<0.05), with adverse events (AEs) consistent with the NSAID class and no increase over time [1].
• There are no published head-to-head trials against daily NSAIDs (e.g., meloxicam, carprofen); the ~71–75% responder rates are consistent with daily-NSAID literature but must not be read as proven equivalence [1].
• Enflicoxib does not exempt any patient from NSAID-class stewardship: case selection, baseline and ongoing gastrointestinal (GI)/renal/hepatic vigilance, and avoidance of NSAID stacking all still apply — and the long half-life that enables weekly dosing also lengthens washout if an AE occurs [1][2].

Drug facts

• Class: COX-2 selective NSAID (coxib class); EMA pharmacotherapeutic group "anti-inflammatory and anti-rheumatic products" [2].
• Mechanism of action: Selective inhibition of cyclo-oxygenase-2 (COX-2), reducing prostaglandin-mediated pain and inflammation [1][2].
• Route / interval: Oral tablet; once-weekly maintenance after an initial loading dose. The extended interval reflects pharmacokinetics that sustain effective tissue/plasma concentrations across a 7-day cycle. Defer to the current Daxocox product information for exact mg/kg loading and maintenance figures [2].
• Indication: Treatment of pain and inflammation associated with osteoarthritis in dogs [2].
• Approval: EMA centrally authorised; CVMP positive opinion 19 February 2021, EPAR first published 16 July 2021, product number EMEA/V/C/005354 [2].
• Contraindications / AEs: Class-typical NSAID precautions apply (see the dedicated section below); consult the current Daxocox product information for the labelled contraindication and adverse-reaction list [2].

Efficacy: what the pivotal field study shows

The long-term evidence base is a prospective, multisite, blinded, randomised, placebo-controlled, parallel-group field study [1]. A total of 109 client-owned dogs with clinical and radiographic signs of osteoarthritis (present for at least 3 weeks) were enrolled and randomised 3:1 to enflicoxib or placebo administered once weekly over 6 months; 78 completed all visits. Veterinary assessment used a clinical sum score (CSS) and owners completed the Canine Brief Pain Inventory (CBPI).

CSS responder rates for enflicoxib were 71.6%, 74.6%, and 71.6% on days 44, 135, and 189 respectively, each significantly higher than placebo (41.7%, 33.3%, and 20.8%; p<0.05 at every timepoint) [1]. Owner-assessed treatment response followed the same trajectory and reached significance versus placebo after 2 weeks of treatment [1].

A clinically useful pattern sits inside these numbers: the placebo responder rate declined progressively across the study (41.7% → 33.3% → 20.8%) while the enflicoxib group held steady (71.6–74.6%). The stable active-arm response argues against tachyphylaxis across the 6-month window and widens the active-versus-placebo gap over time — a durability narrative that is directly useful when setting owner expectations for long-term therapy [1].

A note on timepoint labelling. Some secondary summaries of this trial describe the assessments as "weeks 4, 8, 12." The primary publication reports a 6-month study with assessments on days 44, 135, and 189; the day-based, 6-month framing is authoritative and is used throughout this page [1].

Comparators: how it sits among canine OA drugs

Enflicoxib is one of several COX-2 selective NSAIDs for canine OA; its differentiator is dosing convenience, not a demonstrated efficacy edge. No head-to-head randomised trials compare enflicoxib with daily NSAIDs such as meloxicam or carprofen [1]. Its field responder rates (~71–75%) fall within the range reported for daily NSAIDs in comparable OA populations, but cross-trial comparison is confounded by differing populations, outcome instruments, and placebo behaviour, so prescribers should not assume equivalence to a specific daily agent without reviewing direct comparative data [1].

Within a broader analgesic ladder, enflicoxib can be positioned alongside — or substituted for — other pharmacological options depending on the case: the EP4 antagonist grapiprant, other coxibs such as robenacoxib, and the anti-nerve-growth-factor monoclonal bedinvetmab. The choice among these turns on GI/renal/hepatic risk, monitoring capacity, concurrent medications, and client factors rather than on any single responder-rate figure.

Safety and adverse events

In the 6-month field study, the incidence and type of AEs matched earlier, shorter enflicoxib studies and the expectations for the NSAID class, with no tendency to increase over the 6 months and no relevant changes in haematology, biochemistry, or urinalysis [1]. As with the coxib class generally, gastrointestinal signs are the predominant class-associated risk to counsel owners about and to monitor [1].

The COX-2 selective mechanism does not place enflicoxib outside NSAID-class safety principles [1][2]. Two points deserve emphasis in practice:

• The long-acting pharmacology cuts both ways. The same distribution/elimination profile that permits weekly dosing means the drug cannot simply be stopped and cleared the next day if an adverse reaction develops; effective washout is correspondingly longer than for a daily NSAID [1][2].
• Class stewardship is unchanged by the convenient schedule. Baseline assessment, avoidance of NSAID stacking (including corticosteroid overlap), and structured re-checks remain mandatory regardless of dosing interval.

Special populations and multimodal use

The trial population was client-owned dogs with established clinical and radiographic OA of at least 3 weeks' duration [1]; the evidence does not extend to specific high-risk subgroups. Patients with pre-existing GI, renal, or hepatic compromise, dehydration, or relevant concurrent therapy warrant the same caution the coxib class demands, and dosing in any individual should follow the current label.

Where a multimodal plan is appropriate, enflicoxib sits comfortably alongside non-pharmacological pillars — weight management, physical rehabilitation, and environmental modification — and adjunctive analgesics, with anti-NGF antibodies and EP4 antagonists available as alternative or complementary pharmacological components. The once-weekly schedule can simplify the pharmacological arm of such plans without narrowing the rest of it.

Contraindications, precautions & PK

• Pharmacokinetics: Enflicoxib's long effective half-life sustains therapeutic exposure across the 7-day interval after loading — the mechanistic basis for weekly dosing and, equally, for its prolonged washout [1][2]. Exact PK parameters and the labelled loading/maintenance regimen belong to the current product information, not to any secondary summary.
• Precautions: Standard NSAID cautions apply — pre-existing or suspected GI ulceration/bleeding, renal or hepatic dysfunction, hypovolaemia/dehydration, and concurrent nephrotoxic or ulcerogenic drugs. Do not co-administer with other NSAIDs or corticosteroids.
• Monitoring: Baseline history/exam and, where indicated, renal/hepatic bloodwork; owner counselling on GI warning signs; periodic re-assessment during chronic use. The field study saw no clinically relevant lab shifts over 6 months, but this does not remove the need for individualised monitoring [1].
• Labelled contraindications: Consult the current Daxocox product information for the definitive contraindication and adverse-reaction list [2].

Practical decision support

• Best-fit candidates: Dogs with confirmed OA in whom NSAID therapy is appropriate and where daily dosing is the adherence bottleneck — fractious patients that resist daily handling, owners with physical or cognitive limitations, and multidog households where individual daily dosing is impractical [1].
• Before starting: Confirm the OA diagnosis, screen for GI/renal/hepatic risk, reconcile concurrent medications to exclude NSAID/steroid overlap, and set expectations using the durability data (stable effect maintained through 6 months) [1].
• Counselling anchors: Weekly rhythm aids adherence; GI signs are the AE to report promptly; the long half-life means an adverse reaction is not cleared overnight, so owners should contact the clinic rather than simply skipping the next dose [1][2].
• Guideline framing: Anchor NSAID selection and monitoring in current WSAVA guidance and the product label rather than in any single responder-rate figure; treat cross-trial efficacy comparisons as hypothesis-generating, not confirmatory [1].

Frequently Asked Questions

What is enflicoxib (Daxocox) and how is it dosed? Enflicoxib is a COX-2 selective NSAID of the coxib class, marketed as Daxocox tablets for dogs. It is given orally once weekly for maintenance after an initial loading dose, rather than daily like most canine NSAIDs. Confirm the exact loading and maintenance figures against the current product label [2].

What is enflicoxib approved for, and by whom? The EMA centrally authorised Daxocox for the treatment of pain and inflammation associated with osteoarthritis in dogs. The CVMP issued a positive opinion on 19 February 2021 and the EPAR was first published on 16 July 2021 (EMEA/V/C/005354) [2].

How effective is enflicoxib over the long term? In a 6-month multicentre, blinded, randomised, placebo-controlled field study (n=109), CSS responder rates were 71.6%, 74.6%, and 71.6% on days 44, 135, and 189 — all significantly higher than placebo (41.7%, 33.3%, 20.8%; p<0.05). Owner-assessed response reached significance after 2 weeks [1].

Does the effect hold up over time, or does tolerance develop? The active-arm responder rate stayed stable (71.6–74.6%) while the placebo rate fell from 41.7% to 20.8%, consistent with a durable analgesic effect and no tachyphylaxis across the 6-month window [1].

How does once-weekly enflicoxib compare with daily NSAIDs like meloxicam or carprofen? There are no published head-to-head trials. The ~71–75% field responder rates are broadly consistent with daily-NSAID literature, but cross-trial comparison does not establish equivalence to any specific daily agent — interpret cautiously [1].

Is enflicoxib well tolerated in dogs with OA? In the pivotal field study, AE incidence and type were comparable to other NSAIDs and to earlier enflicoxib data, with no increase over 6 months and no relevant haematology, biochemistry, or urinalysis changes. Gastrointestinal signs are the main class-associated risk; standard NSAID precautions and monitoring still apply [1].

What should I know about the long half-life if an adverse event occurs? The pharmacokinetics that allow weekly dosing also lengthen washout: the drug cannot be stopped and cleared the next day. Counsel owners to contact the clinic if GI or other warning signs appear rather than just skipping the next dose [1][2].

Which patients benefit most from the weekly schedule? Dogs for whom NSAID therapy is appropriate but daily administration is the adherence barrier — fractious patients, owners with physical limitations, and multidog households — gain the most, provided GI/renal/hepatic screening and monitoring follow the same class principles [1].

Changelog

• 2026-06-11: First published (hub).
• 2026-07-06: Consolidated two dated field-data dispatches (2026-06-13 GI tolerability/durability; 2026-06-14 once-weekly compliance) into this evergreen hub. Added dedicated efficacy, comparator, safety/AE, special-populations, PK/precautions, and decision-support sections; folded in the stable-enflicoxib-vs-declining-placebo durability finding and the "no head-to-head vs daily NSAIDs" caveat; expanded the FAQ. Resolved a timepoint-labelling discrepancy between the dispatches ("weeks 4/8/12") and the primary source — the trial is a 6-month study assessed on days 44/135/189, verified against Salichs 2024 [1] and the EMA EPAR [2].